Familial hypercholesterolaemia: identification and management

[2008] 1.4.3.6 Serum cholesterol concentrations should not be measured routinely during pregnancy. [2008] 1.4.3.7 Women with FH who are pregnant should be advised on the potential risks and benefits of re-starting lipid-modifying drug therapy for the mother and breastfed infant. Resins are the only lipid-modifying drug therapy that should be considered during lactation. [2008] 1.5 Ongoing assessment and monitoring 1.5.1 Review 1.5.1.1 All people with FH should be offered a regular structured review that is carried out at least annually. [2008] 1.5.1.2 A baseline electrocardiogram (ECG) should be considered for adults with FH. [2008] 1.5.1.3 Healthcare professionals should record the progress of cascade testing among the relatives of a person with FH as part of the structured review. This should include at least the first- and second-degree relatives- and, when possible, third- degree biological relatives. If there are still relatives who have not been tested, further action should be discussed. [2008] 1.5.1.4 Healthcare professionals should update the family pedigree of a person with FH and note any changes in the coronary heart disease status of their relatives as part of the structured review. This should include at least the first- and second- and, when possible, third-degree biological relatives. [2008] 1.5.1.5
